ReviewStem cell research & therapy2026
Role of microRNAs in cisplatin response of cancer stem cells.
Review in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cisplatin (CDDP)-based chemotherapy remains a cornerstone of cancer treatment, but its efficacy is often limited by the development of chemo resistance that is mainly associated with cancer stem cells (CSCs). MicroRNAs (miRNAs) have emerged as pivotal post-transcriptional regulators of gene expression, critically influencing key cellular processes, including drug response. This review aims to provide a comprehensive analysis of the current evidence elucidating the role of specific miRNAs in governing the CDDP response of CSCs. We conducted a systematic assessment of all available scientific literature databases up to (Nov 2025) to identify relevant studies. Our analysis reveals that miRNAs function as a dynamic network, either promoting or reducing CDDP resistance in CSCs through regulation of signaling pathways, apoptosis, DNA repair pathways, and ABC drug transporters. We identified several consistently reported oncomiRs (e.g., miR-21, miR-765, and miR-132) that were up regulated in CSCs and confer CDDP resistance. Conversely, tumor-suppressor miRNAs were frequently down regulated and their re-expression re-sensitized CSCs to CDDP. This comprehensive review consolidates the compelling evidence that miRNAs are central regulators of CDDP response in CSCs. Understanding this intricate regulatory network provides a robust foundation for developing novel therapeutic strategies, such as miRNA-based mimics or inhibitors (anti-miRs) to overcome CDDP resistance in CSCs improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.